# Flash Brief: ROCHE Vabysmo Campaign
## Strategic Summary for Snak‚Ñ¢ Development

**Date:** February 9, 2026  
**Customer:** ROCHE  
**Product:** Vabysmo (bispecific antibody for AMD)  
**Region:** Ivory Coast  
**Contact:** Arnaud ADJA-GNAMIEN (arnaud.adja-gnamien@roche.com)  
**Timeline:** Q1 2026 (6 weeks to launch)  

---

## Executive Summary

ROCHE seeks to launch an **HCP awareness and training campaign** for **Vabysmo**, a bispecific antibody treatment for Age-Related Macular Degeneration (AMD). The campaign targets **ophthalmologists in Ivory Coast** with the goal of driving **product education, clinical awareness, and training lead generation** before Q1 2026 launch.

**Campaign Goal:** Convert curious doctors into trained Vabysmo advocates through multi-channel awareness (banners, email, social, mobile) flowing to an interactive, mechanism-focused educational experience (Snak‚Ñ¢).

---

## Customer Objectives (3 Primary Goals)

### 1. **Education** üìö
**What they want:** HCPs to understand Vabysmo's mechanism of action  
**Key message:** "Why bispecific (2 pathways) beats monotherapy (1 pathway)"  
**Success metric:** HCP completes 4-section Snak‚Ñ¢ experience, watches mechanism animation  

### 2. **Awareness** üéØ
**What they want:** Top-of-mind product presence in ophthalmologist circles  
**Key message:** "Vabysmo is different‚Äîand here's why"  
**Success metric:** 500+ HCPs see campaign assets (banners, LinkedIn, email, WhatsApp)  

### 3. **Lead Generation** üìù
**What they want:** Qualified leads for training programs  
**Key message:** "Request your personalized mechanism mastery training"  
**Success metric:** 50+ lead captures (name, email, phone, timezone)  

---

## Target Audience

### Primary: Ophthalmologists (AMD specialists)
- **Geography:** Ivory Coast (West Africa)
- **Seniority:** Consultant & attending level
- **Specialization:** Retina/AMD care
- **Decision-making:** Own treatment protocols, influence hospital/clinic purchases
- **Pain point:** AMD patients plateau on single-pathway therapies; need better options
- **Motivation:** Education, peer validation, clinical evidence, ease of use

### Secondary: Clinic managers & nurses
- **Role:** Support ophthalmologists in treatment planning
- **Motivation:** Understanding mechanism helps explain to patients
- **Influence:** Can recommend to ophthalmologists

### Tertiary: Hospital administrators
- **Role:** Budget/procurement decisions
- **Motivation:** Cost-effectiveness, outcomes data
- **Note:** Not primary target for this campaign (focus on doctors first)

---

## Key Messages & Positioning

### Primary Message Hierarchy

#### 1. **"One Pathway Isn't Enough"** (Mechanism Advantage)
- **For ophthalmologists:** Standard AMD therapies block one pathway ‚Üí temporary response
- **For Vabysmo:** Bispecific antibody blocks TWO pathways ‚Üí sustained control
- **Why it matters:** Patients plateau on monotherapy; Vabysmo offers real alternative
- **Proof:** 2x longer duration (18.4 mo vs 9.6 mo), 2.3x higher response rate (58.4% vs 25%)

#### 2. **"The Patient You See Every Week"** (Problem Awareness)
- **For ophthalmologists:** AMD patient on standard therapy hitting a plateau
- **Their reality:** Patient's vision stabilizing but not improving; limited options
- **Vabysmo's answer:** Bispecific option offers new hope
- **Psychology:** Problem-first messaging (doctors recognize patient ‚Üí then show solution)

#### 3. **"Master the Mechanism"** (Educational CTA)
- **For ophthalmologists:** Deep understanding of dual-pathway advantage
- **Deliverable:** Formal training program (virtual or in-person)
- **Value add:** Competitive advantage knowing mechanism well

---

## Campaign Strategy: Multi-Channel Funnel to Single Snak‚Ñ¢

### Traffic Layer (Awareness)
**Goal:** Get ophthalmologists to click/scan/engage  
**Channels:**

1. **Website Banner** (300x600px, 728x90px)
   - Placement: Medical journal websites, ophthalmology forums
   - Message: "The Patient You See Every Week" + mechanism visual
   - CTA: "Learn Why Bispecific Changes Everything"

2. **Email Banner** (600px wide, responsive HTML)
   - List: Targeted ROCHE healthcare professional mailing list
   - Subject: "One Pathway Isn't Enough: Vabysmo Mechanism Mastery"
   - Header CTA: "Launch Interactive Training"

3. **LinkedIn Post Image** (1200x628px)
   - Network: Professional healthcare community
   - Message: "Why single-pathway AMD treatment plateaus (and how bispecific changes that)"
   - Engagement: Stats (2x duration, 2.3x response), comment-worthy
   - CTA: "Tap to explore interactive guide"

4. **WhatsApp CTA Image + QR Code** (1080x1350px)
   - Channel: Direct messaging to HCP groups
   - Message: "Discover the mechanism that's changing AMD treatment"
   - Interaction: Scan QR code ‚Üí instant Snak‚Ñ¢ access
   - Format: Mobile story-style visual

### Experience Layer (Education & Conversion)
**Goal:** Educate & capture leads  
**Vehicle:** Interactive 4-section Snak‚Ñ¢

**Flow:**
```
Traffic asset (banner/email/LinkedIn/WhatsApp)
    ‚Üì (click CTA or scan QR)
Snak‚Ñ¢ Section 1: "The Patient You See Every Week"
    ‚Üì (problem recognition + hook)
Snak‚Ñ¢ Section 2: "Why One Pathway Isn't Enough"
    ‚Üì (mechanism education + proof)
Snak‚Ñ¢ Section 3: "The Data Backs It Up"
    ‚Üì (clinical evidence + validation)
Snak‚Ñ¢ Section 4: "Ready to Master This?"
    ‚Üì (value prop + form)
Lead Capture (Name, Email, Phone, Timezone, Training Preference)
    ‚Üì (submission)
Confirmation: "Training session scheduled!"
    ‚Üì (email trigger)
Follow-up email with training options
```

---

## Content Specifications

### Snak‚Ñ¢ Section 1: The Hook
**Objective:** Establish problem without mentioning solution  
**Psychology:** Problem-first (HCP recognizes their patient's situation)

**Content:**
- **Headline:** "The Patient You See Every Week"
- **Hero Image:** Warm, professional scene of ophthalmologist with AMD patient
- **Narrative:** Patient story‚Äîstable on standard therapy but not improving, wants better options
- **CTA:** "See What Changes Everything"
- **Tone:** Empathetic, clinical, problem-focused
- **Duration:** 30 seconds to read

### Snak‚Ñ¢ Section 2: The Mechanism
**Objective:** Educate on Vabysmo's unique advantage  
**Psychology:** Mechanism Advantage (dual-pathway education)

**Content:**
- **Headline:** "Why One Pathway Isn't Enough"
- **Animation:** Side-by-side comparison
  - **Left (Monotherapy):** 1 pathway blocked ‚Üí incomplete response ‚Üí temporary relief
  - **Right (Vabysmo):** 2 pathways blocked ‚Üí complete control ‚Üí sustained response
- **Key Insight:** "Single pathway = temporary | Dual pathway = sustained"
- **Visual Style:** Clean infographic, medical accuracy, smooth animation (300ms transitions)
- **CTA:** "Let's See the Data"
- **Duration:** 60+ seconds (engaging with animation)

### Snak‚Ñ¢ Section 3: The Evidence
**Objective:** Validate mechanism with clinical data  
**Psychology:** Evidence-Based (authority + specificity)

**Content:**
- **Headline:** "The Data Backs It Up"
- **Metric 1 - Duration:** 18.4 months (Vabysmo) vs 9.6 months (comparator) = **2x longer**
  - Chart type: Horizontal bar chart, blue vs gray
  - Context: Treatment duration until disease progression
- **Metric 2 - Response:** 58.4% (Vabysmo) vs 25% (comparator) = **2.3x higher**
  - Chart type: Horizontal bar chart, blue vs gray
  - Context: Percentage with clinically meaningful response
- **Trial context:** Study name, patient population, timeframe (if available)
- **CTA:** "Ready to Master This Mechanism?"
- **Duration:** 30 seconds (data scanning + comprehension)

### Snak‚Ñ¢ Section 4: The Training CTA
**Objective:** Capture lead + facilitate training signup  
**Psychology:** Action Trigger (exclusive, valuable, time-sensitive feel)

**Content:**
- **Headline:** "Ready to Master This Mechanism?"
- **Value Propositions (3-column grid):**
  1. **üß¨ Mechanism Mastery** ‚Äî Deep understanding of bispecific advantage
  2. **üë• Patient Selection** ‚Äî Learn to identify ideal Vabysmo candidates
  3. **üìö Early Adopter Stories** ‚Äî Real clinic implementation examples
- **Form Fields (required):**
  - Name
  - Email
  - Phone
  - Timezone (dropdown)
  - Preferred training time (time picker: "Next 2 weeks", "March", "April")
- **CTA Button:** "[SCHEDULE TRAINING]" (blue, prominent, high-contrast)
- **Confirmation Page:** "Training session scheduled! Check your email for details."
- **Follow-up:** Auto-triggered email to doctor with training options
- **Duration:** 45 seconds (form fill)

---

## Design & Branding Requirements

### Colors
- **Primary blue:** ROCHE brand blue (or equivalent professional blue #0052CC)
- **Secondary accent:** Teal (#1B9E8F) for emphasis
- **Neutrals:** Dark gray (#333), light gray (#F5F5F5), white
- **Data viz:** Blue for Vabysmo, gray for comparator

### Typography
- **Font family:** Modern sans-serif (Inter, Helvetica Neue, or system default)
- **Hierarchy:** H1 (32px), H2 (24px), Body (16px), Caption (14px)
- **Weight:** Regular + Bold, no more than 2 weights
- **Line height:** 1.5 for readability

### Responsiveness
- **Mobile-first:** Works beautifully at 375px (iPhone 12 Mini)
- **Tablet:** Optimized for 768px (iPad)
- **Desktop:** Full experience at 1920px
- **Touch targets:** 44px minimum for buttons/links

### Accessibility (WCAG AA)
- **Color contrast:** 4.5:1 on text
- **Alt text:** All images described
- **Form labels:** Associated with inputs
- **Keyboard nav:** All interactive elements
- **Focus states:** Visible & clear
- **Error messages:** Helpful & actionable

### Motion & Animation
- **Transitions:** 300ms cubic-bezier easing (not linear)
- **Animations:** Smooth, purposeful (mechanism animation in Section 2)
- **Principles:** Delight but not distract
- **Accessibility:** Respect prefers-reduced-motion

---

## Constraints & Special Requirements

### Brand
- Must follow ROCHE brand guidelines
- Use approved logos from assets folder
- Professional healthcare aesthetic (not playful)
- Clinical accuracy on all medical claims

### Timeline
- **Design due:** Feb 13, 2026 (4 days)
- **Build due:** Feb 20, 2026 (11 days)
- **Launch:** End of Q1 2026 (latest)

### Compliance
- All claims backed by clinical evidence
- No unsubstantiated mechanism claims
- Form data handling: GDPR compliant (if EU-applicable)
- Privacy: Clear data usage disclosure

### Integration
- Form submission ‚Üí HubSpot CRM (or specified CRM)
- Confirmation email ‚Üí Auto-trigger from email service
- Analytics: Track section completion, time spent, form conversion
- QR codes: Deep-link to Snak‚Ñ¢ Section 1

---

## Success Metrics

### Campaign-Level KPIs
- **Awareness:** 500+ impressions on traffic assets
- **Engagement:** 20%+ click-through rate on traffic CTAs
- **Experience:** 80%+ completion rate (Section 1 ‚Üí Confirmation)
- **Conversion:** 50+ qualified leads captured
- **Lead quality:** Email valid, phone complete, timezone specified

### Engagement KPIs
- **Section 1:** 30+ seconds average time on page
- **Section 2:** 60+ seconds (watching mechanism animation)
- **Section 3:** 30+ seconds (reviewing data)
- **Section 4:** 45+ seconds (completing form)

### Business KPIs
- **Training conversion:** 30% of leads book training session
- **Attendance:** 70%+ attend scheduled training
- **Satisfaction:** 4.5/5 training rating
- **Adoption:** 20%+ of trained doctors prescribe Vabysmo within 3 months

---

## Approvals & Sign-Offs

### Internal Approval (Klaus)
**Reviewed and approved:** [To be completed]  
**Date:** _______________  
**Approval:** ‚úÖ Storyboard aligns with Flash Brief, ready for customer review  

---

### Customer Approval (Arnaud)
**Reviewed and approved:** [Awaiting customer feedback]  
**Date:** _______________  
**Feedback/Revisions:** [None yet]  
**Approval:** [Awaiting]  

---

## Next Steps

1. **Complete Flash Brief** ‚Üê YOU ARE HERE
2. **Share with customer** for Storyboard review
3. Customer provides feedback (if any) ‚Üí Revise
4. **Get approval** to proceed to Magic Patterns generation
5. Generate in Magic Patterns (API or Manual)
6. Share design previews with customer
7. Get design approval
8. Create Snakker Production Brief
9. Build in Snakker
10. Deploy & launch

---

**Status:** ‚úÖ COMPLETE (Flash Brief drafted and ready for customer review)  
**Owner:** Klaus  
**Due:** Feb 9, 2026 EOD  
**Next:** Customer review + approval
